Today we are talking to Jeremy Levin. Jeremy is chairman and CEO of Ovid Therapeutics, focused on rare and orphan disease of the CNS. He is the immediate past chair of BIO.
Jeremy has a storied career in biotech having served as president and CEO of Teva Pharmaceutica’s, a member of the exec committee of BMS where he had global responsibilities for strategy, alliances and transactions. There he devised the “String of Pearls” BD strategy which led to the acquisition of Medarex and opened the path to the successful development of the first i-onc drugs. Prior to BMS Jeremy was head of global BD and strategic alliances at Novartis. In his spare time, amazing he has any, he runs a successful Black Angus farm from which, as I understand it, many biotech CEOs get their steaks!
Between the Biotech Waves